Engaging with patients in a genuine and transparent way is tough. Really tough. It’s challenging for all healthcare stakeholders - payers, providers, and industry. From a medtech perspective, we often times get stuck in a certain mindset when trying to engage with patients. Whether it’s a continuous glucose [Read More]
Demystifying Value-Based Healthcare – A Physician Expert Explains All (with Real-World Examples)
CMS has an objective to shift 50% of all reimbursement services from fee-for-service to alternative, value-based methods by 2018. And bundled payment models, according to Dr. Dan Mazanec, will be the principal driver of this transformative initiative. But the topic of value-based healthcare can be pretty [Read More]
Is Off-Label Promotion Now Legal? What the Recent Criminal Case Against Vascular Solutions Means for Medtech
For as long as I can remember, at every company meeting I've ever been to, the topic of off-label promotion is always covered. Whether it was new-hire orientation, a national sales meeting, or some other large commercial event, the dissemination of off-label information was always presented as not only a fireable [Read More]
4 Medical Device M&A Deals I’d Like to See
On the heals of the Abbott - St. Jude deal, should Boston Scientific go in a completely different direction? What other medtech M&A deals should come to fruition? And how can medical device companies compete in the new era of bundled, value-based programs? These are just some of the topics covered in the latest [Read More]
After Selling 2 Cardiovascular Companies for Over $1 Billion, Duke Rohlen is Now Hoping to do the Same with Spirox and Advanced Cardiac Therapeutics
Jack Dorsey received quite a bit of attention when he was recently announced as CEO of Twitter. Why? Because that made him CEO of 2 of the most rapidly-growing tech. companies in Silicon Valley at the same - Twitter and Square. Well, medtech’s version of Jack Dorsey might be Duke Rohlen. Duke led FoxHollow [Read More]
Doctors Send $1.6M Per Year to Hospitals Despite the Value-Based Push
In this issue, learn how doctors are still an economic asset for most hospitals. Also, check out the piece written by Dr. Gary Guthard, the CEO of Intuitive Surgical. You also might find MD&DI's article about value analysis teams to be worth a read. I've included a few other pieces that might deserve your [Read More]
From an Idea on the Back of a Napkin to an Eventual $240 Million Exit – The Amazing Story of Sapheon
I'll be candid. This is an interview I've wanted to do for quite some time. During my time at Covidien, I considered myself fortunate to be involved with the acquisition of Sapheon, a startup company that manufactured a disruptive therapy for venous reflux. The more I learned about Sapheon through the diligence [Read More]
Survey: Medical Reps Like the Money, Not Their Bosses
In this issue, learn why medical device reps like their jobs, just not their bosses. Also, check out S2N's piece on advice for early-stage medtech CEOs. You also might find MD&DI's article on the robotic space pretty interesting. I've included a few other pieces that might deserve your attention as well. [Read More]
After Selling Their First Spin-out (Corventis) to Medtronic, this Team is Aiming for an Even Bigger Splash in the Wearables Space
When most people think of the wearables space, devices like the Fitbit or the Apple Watch come to mind. But over the past few years, there’s been a lot of development with respect to wearable devices that were designed for the traditional healthcare market. Medtronic launched the SEEQ device. Although implantable, [Read More]
Value-Based Payments: Don’t Ignore the Signs!
In this issue, learn why you can't afford to ignore the value-based train that's coming down the tracks. I've also highlighted a few different pieces regarding direct-to-patent changes within healthcare. And lastly, if you have questions regarding the 510(k) process, don't forget to check out these [Read More]